MyoKardia initiated with a Buy at BofA/Merrill. BofA/Merrill analyst Tazeen Ahmad initiated MyoKardia with a Buy and $71 price target saying the company focuses on treating cardiovascular diseases and has two clinical assets, mavacamten and MYK-491, that could become the first FDA therapies approved in hypertrophic and dilated cardiomyopathy. Ahmad believes MyoKardia’s investment by Sanofi in mavacamten as a de-risking event.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.